- VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after subcutaneous dosing in healthy volunteers, with 74% reduction at peak -
- VRDN-008 demonstrated an
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will
- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -
- Elegrobart Biologics License Application (BLA) submission on track for Q1 2027 -
-
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it
- Lumvoa™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. -
- Elegrobart, potentially the first subcutaneous
DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives
- First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED -
- In two pivotal phase 3 clinical trials, Lumvoa treatment showed rapid, consistent, and
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced that it has
- PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready -
- Marketing Authorization Application (MAA) for veligrotug in TED submitted to the European
- REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect -
- Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates (PRR) at week 24, respectively, versus 15%
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Viridian Therapeutics, Inc. (NASDAQ:VRDN). The investigation focuses on Viridian's
- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect -
- Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18%
- PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch -
- Marketing Authorization Application (MAA) for
